Claims for Patent: 9,309,275

Summary for Patent: 9,309,275

Title:	3\'-deoxy nucleosides for the treatment of HCV
Abstract:	Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3\'-deoxy nucleoside compounds according to Formula 3001a or 3001b: ##STR00001## or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Base.sup.1 and Base.sup.2 are as provided herein.
Inventor(s):	Stewart; Alistair James (Lincoln, MA), Moussa; Adel M. (Burlington, MA), Mayes; Benjamin Alexander (Boston, MA), Alexandre; Francois-Rene (Montpellier, FR), Surleraux; Dominique (Wauthier-Braine, BE), Parsy; Christophe Claude (Jacou, FR), Pierra; Claire (Montarnaud, FR), Dukhan; David (Saint Gely du Fesc, FR), Gosselin; Gilles (Montpellier, FR)
Assignee:	IDENIX PHARMACEUTICALS LLC (Cambridge, MA) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris, FR) UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES (Montpellier, FR)
Application Number:	14/195,388
Patent Claims:	1. A compound according to Formula Ia or Ib: ##STR00088## or a pharmaceutically acceptable salt, solvate, tautomeric form, or polymorphic form thereof, wherein: Base.sup.1 is ##STR00089## or a tautomeric form thereof; Base.sup.2 is ##STR00090## or a tautomeric form thereof; R.sup.4 is hydrogen, hydroxyl, amino, or alkoxyl; R.sup.5 is hydrogen, hydroxyl, or alkoxyl; R.sup.6 is hydrogen, halogen, or alkyl; R.sup.7 is hydrogen or --NH.sub.2; PD is ##STR00091## W is S or O; each of X and Y is independently hydrogen, --OR.sup.1, --SR.sup.1, --NR.sup.1R.sup.2, or an N-linked amino acid, or ester thereof; each R.sup.1 is independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; and each R.sup.2 is independently hydrogen or alkyl. 2. The compound of claim 1 according to formula II: ##STR00092## or a pharmaceutically acceptable salt, solvate, tautomeric form, or polymorphic form thereof. 3. The compound of claim 1, wherein W is O. 4. A compound according to formula III or IV: ##STR00093## or a pharmaceutically acceptable salt, solvate, tautomeric form, or polymorphic form thereof, wherein: Ar.sup.1 is aryl or heteroaryl; R.sup.3 is alkyl; Base.sup.2 is ##STR00094## or a tautomeric form thereof; R.sup.4 is hydrogen, hydroxyl, amino, or alkoxyl; R.sup.5 is hydrogen, hydroxyl, or alkoxyl; R.sup.6 is hydrogen, halogen, or alkyl; and Y is hydrogen, --OR.sup.1, --SR.sup.1, --NR.sup.1R.sup.2, or an N-linked amino acid, or ester thereof. 5. The compound of claim 4, wherein R.sup.3 is branched hydroxyalkyl. 6. The compound of claim 4, wherein R.sup.3 is --C(CH.sub.3).sub.2CH.sub.2OH. 7. The compound of claim 1 according to any of Formulas V-VIII: ##STR00095## or a pharmaceutically acceptable salt, solvate, tautomeric form, or polymorphic form thereof. 8. The compound of claim 1 according to any of Formulas IX-XI: ##STR00096## or a pharmaceutically acceptable salt, solvate, tautomeric form, or polymorphic form thereof. 9. The compound of claim 1 according to Formula (Ia): ##STR00097## or a pharmaceutically acceptable salt, solvate, tautomeric form or polymorphic form thereof. 10. The compound of claim 1 according to Formula Iai or Iaii: ##STR00098## or a pharmaceutically acceptable salt, solvate, tautomeric form, or polymorphic form thereof. 11. The compound of claim 1 according to any of formulas (1a), (2a), (102), and (4): ##STR00099## or a pharmaceutically acceptable salt, solvate, tautomeric form, or polymorphic form thereof. 12. A compound according to Formula (3): ##STR00100## or a pharmaceutically acceptable salt, solvate, tautomeric form or polymorphic form thereof. 13. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient, carrier, or diluent. 14. The pharmaceutical composition of claim 13, wherein the composition is an oral formulation. 15. A method for the treatment of a host infected with a hepatitis C virus, comprising the administration of an effective treatment amount of a compound of claim 1. 16. The method of claim 15, wherein the host is a human. 17. The method of claim 16, wherein the administration directs a substantial amount of the compound, or pharmaceutically acceptable salt thereof, to a liver of the host. 18. The method of claim 15, wherein the compound is administered in combination or alternation with a second anti-viral agent, wherein the second anti-viral agent is an interferon, a nucleotide analogue, a polymerase inhibitor, an NS3 protease inhibitor, an NS5A inhibitor, an entry inhibitor, a non-nucleoside polymerase inhibitor, a cyclosporine immune inhibitor, an NS4A antagonist, an NS4B-RNA binding inhibitor, a locked nucleic acid mRNA inhibitor, a cyclophilin inhibitor, or a combination thereof. 19. The method of claim 18, wherein the second anti-viral agent is IDX-719, TMC435, PSI-7977, telaprevir, boceprevir, interferon alfacon-1, interferon alfa-2b, pegylated interferon alpha 2a, pegylated interferon alpha 2b, ribavirin, or a combination thereof. 20. The method of claim 18, wherein the second anti-viral agent is IDX-719, TMC435, PSI-7977, telaprevir, boceprevir, interferon alfacon-1, interferon alfa-2b, pegylated interferon alpha 2a, pegylated interferon alpha 2b, or a combination thereof, and further wherein the administration is not in combination or alternation with ribavirin. 21. A pharmaceutical composition comprising the compound of claim 4 and a pharmaceutically acceptable excipient, carrier, or diluent. 22. A method for the treatment of a human host infected with a hepatitis C virus, comprising the administration of an effective treatment amount of a compound of claim 4. 23. The compound of claim 1 where each of X and Y is independently hydrogen, --OR.sup.1, --SR.sup.1, --NR.sup.1R.sup.2, or an N-linked amino acid ester. 24. A compound according to Formula Ia or Ib: ##STR00101## or a pharmaceutically acceptable salt, solvate, tautomeric form, or polymorphic form thereof, wherein: Base.sup.1 is ##STR00102## or a tautomeric form thereof; Base.sup.2 is ##STR00103## or a tautomeric form thereof; R.sup.4 is hydrogen, hydroxyl, --NH.sub.2, --O-(alkyl) or --O-(unsubstituted cycloalkyl); R.sup.5 is hydrogen, hydroxyl, or unsubstituted alkoxyl; R.sup.6 is hydrogen, halogen, or optionally substituted alkyl; R.sup.7 is hydrogen or --NH.sub.2; PD is hydrogen, ##STR00104## W is S or O; each of X and Y is independently hydrogen, --OR.sup.1, --SR.sup.1, --NR.sup.1R.sup.2, an N-linked amino acid, or --NR.sup.X-G(S.sub.C)--C(O)-Q.sup.1; each Q.sup.1 is independently --SR.sup.Y, --NR.sup.YR.sup.Y, or alkoxyl; each R.sup.Y is independently hydrogen or optionally substituted alkyl; each S.sub.C is independently a side chain of a naturally occurring or non-naturally occurring amino acid or is hydrogen, optionally substituted alkyl, arylalkyl, carboxylalkyl, heteroarylalkyl, aminoalkyl, hydroxylalkyl, aminoiminoaminoalkyl, aminocarbonylalkyl, sulfanylalkyl, carbamoylalkyl, alkylsulfanylalkyl, or hydroxylarylalkyl; each G is independently unsubstituted C.sub.1-C.sub.2 alkyl; each R.sup.X is independently hydrogen or R.sup.X and S.sub.C, together with the atoms to which they are attached, combine to form a five-membered heterocyclic ring; each R.sup.1 is independently hydrogen, optionally substituted alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; and each R.sup.2 is independently hydrogen or optionally substituted alkyl; each alkyl is independently an unsubstituted C.sub.1 to C.sub.10 saturated hydrocarbon, unless specified otherwise; and when substituted is substituted with one or more moieties independently selected from halogen, hydroxyl, sulfanyl, --NR.sup.1'R.sup.2' (wherein R.sup.1' and R.sup.2' are independently selected from hydrogen, alkyl, and cycloalkyl), --NH(alkyl), --N(alkyl).sub.2, --NH(aryl), --N(aryl).sub.2, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, and phosphonate; each alkoxy is --OR' where each R' is independently alkyl or cycloalkyl; and each alkoxy is independently optionally substituted, unless specified otherwise; each amino is --NR.sup.1' R.sup.2' or --NR.sup.1', wherein R.sup.1' and R.sup.2' are independently selected from hydrogen, alkyl, and cycloalkyl; each aryl is independently phenyl, biphenyl, or naphthyl and is optionally substituted; and when substituted is substituted with one or more moieties independently selected from halogen, alkyl, haloalkyl, hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, and phosphonate; each cycloalkyl is an optionally substituted monocyclic saturated C.sub.3-15 hydrocarbon or a saturated, bridged or fused bicyclic C.sub.3-15 hydrocarbon; and when substituted is substituted with one or more moieties independently selected from halogen, hydroxyl, sulfanyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, and phosphonate; each heteroaryl is independently a monovalent monocyclic aromatic group with 5 to 20 ring atoms or multicyclic aromatic group that contains at least one aromatic ring with 5 to 20 ring atoms; wherein the monocyclic ring and at least one aromatic ring in the multicyclic ring contains one or more heteroatoms independently selected from O, S, and N in the ring provided that the total number of heteroatoms in each ring is four or less and each ring contains at least one carbon atom; wherein the heteroaryl is bonded to the rest of the molecule through the aromatic ring; and heterocyclic means a monovalent monocyclic non-aromatic ring system, or a bicyclic, tricyclic, or tetracyclic ring system which contains at least one non-aromatic ring and the other ring(s) may be partially saturate, fully saturated, or aromatic, and which bi-, tri- and tetracyclic ring can be fused or bridged; wherein one or more of the non-aromatic ring atoms is a heteroatoms independently selected from O, S, and N and the remaining ring atoms are carbon atoms and where the nitrogen or sulfur atoms may be optionally oxidized and the nitrogen atoms may be optionally quaternized; wherein the ring has 3 to 20 ring atoms; and wherein the heterocyclic is attached to the main structure at any heteroatom or carbon atom which results in the creation of a stable compound.

Details for Patent 9,309,275

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-03-29
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-03-29
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-03-29
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663	10/06/1997		2039-03-29
Hoffmann-la Roche Inc.	PEGASYS COPEGUS COMBINATION PACK	peginterferon alfa-2a and ribavirin		125083	06/04/2004		2039-03-29
Schering Corporation A Subsidiary Of Merck & Co., Inc.	PEGINTRON/ REBETOL COMBO PACK	peginterferon alfa-2b and ribavirin		125196	06/13/2008		2039-03-29